From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.